Loading...
By Joe Elia
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
In treating type 2 diabetes, the American Diabetes Association's advice to start with metformin and add other drugs as needed (in consultation with patients) seems about right, according to a network meta-analysis in JAMA.
Researchers analyzed 300 randomized trials comprising over 118,000 adults; trials' sponsors took active roles in about two thirds. Nine drug classes were analyzed, including metformin, insulins, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, and others. Trials included monotherapy, dual-therapy, or triple-therapy regimens.
Compared with metformin monotherapy or metformin-sulfonylurea dual therapy, no drug class was associated with increased risk for the primary outcome of cardiovascular mortality. Hypoglycemia, a secondary outcome, was associated with sulfonylurea as well as basal insulin monotherapies.
The authors conclude that "all drugs were estimated to be effective when added to metformin," adding that their findings were consistent with American Diabetes Association recommendations.
Comment
LINK(S):
JAMA article (Free abstract)
Background: NEJM Journal Watch General Medicine coverage of ADA guidelines (Your NEJM Journal Watch subscription required)